Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA
Eli Lilly and Company (NYSE: LLY) is hosting a webcast on June 7, 2022, at 11:30 a.m. ET, discussing its diabetes and obesity portfolio. Key topics include results from the tirzepatide SURMOUNT-1 clinical trial and details on Lilly's weekly basal insulin and early-phase incretins. The event will be accessible via the company's Investor website, with a replay available for 90 days following the event. Lilly aims to advance healthcare solutions addressing significant health challenges, including diabetes and obesity.
- Webcast to showcase diabetes and obesity portfolio advancements.
- Focus on positive results from the tirzepatide SURMOUNT-1 clinical trial.
- Access to live and recorded presentations for investor engagement.
- None.
INDIANAPOLIS, May 23, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will host a webcast on Tuesday, June 7, 2022 to discuss the company's diabetes and obesity portfolio and its presentations at the American Diabetes Association's 82nd Scientific Sessions. The webcast will begin at 11:30 a.m. Eastern time and remarks will focus on results from the tirzepatide SURMOUNT-1 clinical trial, as well as Lilly's once-weekly basal insulin and early-phase incretins.
A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days.
About Lilly
Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram, Twitter and LinkedIn. F-LLY
Refer to: | Jordan Bishop; jordan.bishop@lilly.com; 317-473-5712 (Media) |
Kevin Hern; hern_kevin_r@lilly.com; 317-277-1838 (Investors) | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-announces-webcast-to-provide-diabetes-and-obesity-portfolio-update-at-ada-301552841.html
SOURCE Eli Lilly and Company
FAQ
What is the date of Eli Lilly's webcast discussing its diabetes and obesity portfolio?
What time does Eli Lilly's webcast start?
What will be discussed during Eli Lilly's webcast?
Where can I watch the Eli Lilly webcast?
